Ovid Therapeutics OVID

$ 1.05 -0.94%

Quarterly report 2024-Q3
added 11-12-2024

Ovid Therapeutics Balance Sheet 2011-2024 | OVID

Annual Balance Sheet Ovid Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-11 M	-28.3 M	-	-72 M	-41.9 M	-36.5 M	-87.1 M	-51.9 M	-69.9 M	-	-	-	-
Long Term Debt	14.8 M	16 M	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1.25 M	534 K	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	10.2 M	287 K	-	-	-	-	-	-	-	-
Total Current Liabilities	11.5 M	6.99 M	14.8 M	22.1 M	10.5 M	8.84 M	6.02 M	-	-	-	-	-	-
Total Liabilities	56.2 M	23 M	14.8 M	32.3 M	10.8 M	8.84 M	6.02 M	3.73 M	2.31 M	-	-	-	-
Deferred Revenue	-	-	-	2.21 M	-	-	-	-	-	-	-	-	-
Retained Earnings	-278 M	-226 M	-171 M	-294 M	-213 M	-153 M	-101 M	-61.8 M	-13.5 M	-	-	-	-
Total Assets	144 M	155 M	195 M	75.9 M	80.8 M	47.6 M	89.5 M	53 M	70.4 M	-	-	-	-
Cash and Cash Equivalents	27 M	44.9 M	188 M	72 M	41.9 M	36.5 M	87.1 M	51.9 M	-	-	-	-	-
Book Value	87.8 M	132 M	180 M	43.6 M	70 M	38.8 M	83.4 M	49.3 M	68.1 M	-	-	-	-
Total Shareholders Equity	87.8 M	132 M	180 M	43.6 M	70 M	38.8 M	83.4 M	49.3 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Ovid Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	13.8 M	14.1 M	14.4 M	14.8 M	15.1 M	15.4 M	15.7 M	16 M	16.2 M	16 M	15.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	26.4 M	29.2 M	53.3 M	56.2 M	23.7 M	25.5 M	22.4 M	23 M	23 M	25.2 M	26.1 M	14.8 M	10.1 M	11.3 M	16.3 M	32.3 M	32.3 M	32.3 M	32.3 M	10.8 M	10.8 M	10.8 M	10.8 M	8.84 M	8.84 M	8.84 M	8.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.21 M	2.21 M	2.21 M	2.21 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-295 M	-281 M	-290 M	-278 M	-263 M	-251 M	-239 M	-226 M	-214 M	-202 M	-187 M	-171 M	-145 M	-134 M	-118 M	-294 M	-294 M	-294 M	-294 M	-213 M	-213 M	-213 M	-213 M	-153 M	-153 M	-153 M	-153 M	-101 M	-101 M	-101 M	-101 M	-35.9 M	-35.9 M	-35.9 M	-35.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	103 M	118 M	132 M	144 M	125 M	136 M	143 M	155 M	165 M	177 M	191 M	195 M	207 M	218 M	237 M	75.9 M	75.9 M	75.9 M	75.9 M	80.8 M	80.8 M	80.8 M	80.8 M	47.6 M	47.6 M	47.6 M	47.6 M	89.5 M	89.5 M	89.5 M	89.5 M	53 M	53 M	53 M	53 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	15 M	29.7 M	30.8 M	27 M	59.4 M	73.6 M	65 M	44.9 M	60.2 M	74.7 M	169 M	188 M	202 M	212 M	233 M	72 M	72 M	72 M	72 M	41.9 M	41.9 M	41.9 M	41.9 M	36.5 M	36.5 M	36.5 M	36.5 M	87.1 M	87.1 M	87.1 M	87.1 M	51.9 M	51.9 M	51.9 M	51.9 M	69.9 M	-	-	-	4.85 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	76.3 M	88.9 M	78.3 M	87.8 M	101 M	111 M	121 M	132 M	142 M	152 M	165 M	180 M	197 M	207 M	221 M	43.6 M	43.6 M	43.6 M	43.6 M	70 M	70 M	70 M	70 M	38.8 M	38.8 M	38.8 M	38.8 M	89.5 M	89.5 M	89.5 M	89.5 M	53 M	53 M	53 M	53 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	76.3 M	88.9 M	78.3 M	87.8 M	101 M	111 M	121 M	132 M	142 M	152 M	165 M	180 M	197 M	207 M	221 M	43.6 M	43.6 M	43.6 M	43.6 M	70 M	70 M	70 M	70 M	38.8 M	38.8 M	38.8 M	38.8 M	83.4 M	83.4 M	83.4 M	83.4 M	49.3 M	49.3 M	49.3 M	49.3 M	68.1 M	-	-	-	4.74 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency